SHR9352

SHR9352 is a novel, highly selective, and potent cyclic peptide antagonist of the glucagon-like peptide-1 receptor (GLP-1R). It is currently under development by Shanghai Hengrui Pharmaceutical Co., Ltd., a leading pharmaceutical company in China.

Mechanism of Action[edit | edit source]

SHR9352 works by selectively binding to the glucagon-like peptide-1 receptor (GLP-1R), a receptor that plays a crucial role in regulating glucose metabolism. By blocking the action of GLP-1R, SHR9352 can potentially help to control blood glucose levels in patients with type 2 diabetes.

Clinical Development[edit | edit source]

As of the time of writing, SHR9352 is in the early stages of clinical development. Preclinical studies have shown promising results, with SHR9352 demonstrating a high degree of selectivity and potency against GLP-1R. Clinical trials are currently underway to further evaluate the safety and efficacy of this novel cyclic peptide antagonist.

Potential Applications[edit | edit source]

The primary therapeutic application of SHR9352 is in the treatment of type 2 diabetes. By blocking the action of GLP-1R, SHR9352 could potentially help to control blood glucose levels in patients with this condition. However, further research is needed to fully understand the potential benefits and risks of this treatment approach.

References[edit | edit source]

This pharmacology-related article is a stub. You can help WikiMD by expanding it.

‎

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.